BriaCell's Bria-OTS Shows Significant Lung Metastasis Resolution in Breast Cancer Patient

BriaCell Therapeutics reports a remarkable case of lung metastasis resolution in a breast cancer patient treated with Bria-OTS. The 78-year-old patient experienced a complete disappearance of lung metastasis after receiving four doses of the personalized immunotherapy. This breakthrough could pave the way for broader applications of Bria-OTS in cancer treatment. Analysts forecast an average target price of $128.50, implying a 4,315.81% upside from the current price.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced a significant milestone in its Bria-OTS immunotherapy program. The company reported sustained complete resolution of lung metastasis in a 78-year-old patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS [1]. The patient, who had experienced multiple prior treatment failures, achieved 100% resolution of a lung metastasis following four doses of Bria-OTS monotherapy. The complete response was first observed at two months and confirmed at four and six months [1].

The patient has been dosed with 12 cycles of Bria-OTS to date, with no treatment-limiting toxicities observed [1]. This milestone was achieved at the lowest dose level, demonstrating strong single-agent activity in a challenging patient population [2]. The lack of treatment-limiting toxicities is equally important in this elderly patient population, where tolerability often determines whether a therapy can be continued.

Dr. Neal S. Chawla, Director at the Sarcoma Oncology Center and Principal Investigator for the Bria-OTS study, stated, "These results represent an exciting clinical milestone in the Bria-OTS program. We are seeing strong single agent activity in a very challenging population and are eager to explore this approach across more patient subtypes and tumors" [1]. Dr. William V. Williams, President and CEO of BriaCell, added, "We are highly encouraged by this remarkable and durable clinical response, especially at the lowest dose level. This data underscores the therapeutic potential of our Bria-OTS platform, and we look forward to further evaluating it in combination with a checkpoint inhibitor to improve outcomes in patients with advanced breast cancer" [1].

Bria-OTS is a next-generation, off-the-shelf personalized immunotherapy based on BriaCell's lead candidate Bria-IMT, currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673) in patients with metastatic recurrent breast cancer [1]. The trial includes both monotherapy dose escalation and checkpoint inhibition combination dose expansion cohorts.

Analysts have forecasted an average target price of $128.50 for BriaCell Therapeutics, implying a 4,315.81% upside from the current price [2].

References:
[1] https://finance.yahoo.com/news/briacell-patient-achieves-sustained-complete-113000929.html
[2] https://www.stocktitan.net/news/BCTX/bria-cell-patient-achieves-sustained-complete-resolution-of-lung-kpx0tzqaqc78.html